Published in Int J Oncol on April 01, 1998
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs (2006) 1.05
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer (2000) 3.31
Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun (1999) 3.21
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 2.50
DNA strand specificity for UV-induced mutations in mammalian cells. Mol Cell Biol (1989) 2.12
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer (2006) 1.90
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res (1996) 1.83
Cloning, expression, purification and characterization of patatin, a novel phospholipase A. Eur J Biochem (2001) 1.80
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res (1997) 1.79
A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges. Mutagenesis (1992) 1.73
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Strand specificity for UV-induced DNA repair and mutations in the Chinese hamster HPRT gene. Nucleic Acids Res (1991) 1.68
Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res (2001) 1.66
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia (2010) 1.61
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res (1998) 1.47
The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics (1994) 1.46
Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg (2000) 1.43
Identification and characterization of circulating prostate carcinoma cells. Cancer (2000) 1.41
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34
Characterization of the role of IL-6 in the progression of prostate cancer. Prostate (1999) 1.33
Nucleotide sequence determination of point mutations at the mouse HPRT locus using in vitro amplification of HPRT mRNA sequences. Mutat Res (1988) 1.26
Characterization of an X-ray-hypersensitive mutant of V79 Chinese hamster cells. Mutat Res (1988) 1.25
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis (2012) 1.21
Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 1.17
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther (2008) 1.16
Linear dose--response relationships after prolonged expression times in V-79 Chinese hamster cells. Mutat Res (1976) 1.15
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res (1996) 1.14
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res (2001) 1.13
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer (2011) 1.12
Mutagen-sensitive cell lines are obtained with a high frequency in V79 Chinese hamster cells. Mutat Res (1987) 1.10
Mutations induced by X-rays at the HPRT locus in cultured Chinese hamster cells are mostly large deletions. Mutat Res (1985) 1.09
Use of low temperature for growth arrest and synchronization of human diploid fibroblasts. Mutat Res (1984) 1.09
Development of a liquid-holding technique for the study of DNA-repair in human diploid fibroblasts. Mutat Res (1979) 1.08
(6-4) photoproducts and not cyclobutane pyrimidine dimers are the main UV-induced mutagenic lesions in Chinese hamster cells. Mutat Res (1992) 1.08
Phenotypic heterogeneity within the first complementation group of UV-sensitive mutants of Chinese hamster cell lines. Mutat Res (1988) 1.07
Complete androgen blockade for prostate cancer: what went wrong? J Urol (2000) 1.06
Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res (2002) 1.05
Biological and biochemical consequences of the human ERCC-1 repair gene after transfection into a repair-deficient CHO cell line. Mutat Res (1987) 1.02
Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis (2009) 1.00
The use of frequency distributions of cell diameters to characterize cell populations in tissue culture. Exp Cell Res (1967) 0.99
The wavelength dependence of u.v.-induced pyrimidine dimer formation, cell killing and mutation induction in human diploid skin fibroblasts. Carcinogenesis (1986) 0.98
Identification of a new seventh complementation group of UV-sensitive mutants in Chinese hamster cells. Mutat Res (1988) 0.96
Evidence supporting exclusion of the DCC gene and a portion of chromosome 18q as the locus for susceptibility to hereditary nonpolyposis colorectal carcinoma in five kindreds. Cancer Res (1991) 0.96
HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Curr Cancer Drug Targets (2009) 0.94
Molecular analysis of mutations induced by N-ethyl-N-nitrosourea at the HPRT locus in mouse lymphoma cells. Mutat Res (1988) 0.93
Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate (1998) 0.93
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol (2000) 0.93
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol (2012) 0.92
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 0.92
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res (2006) 0.91
Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry (1998) 0.90
Investigation of colon cancers for human papillomavirus genomic sequences by polymerase chain reaction. J Surg Oncol (1992) 0.90
Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology (1999) 0.90
Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. Biochem Biophys Res Commun (2001) 0.90
How variable is a spontaneous mutation rate in cultured mammalian cells? Mutat Res (1994) 0.90
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs (2000) 0.90
Gene therapy of prostate cancer: current and future directions. Endocr Relat Cancer (2002) 0.88
Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology (2000) 0.88
Ataxia-telangiectasia-like Chinese hamster V79 cell mutants with radioresistant DNA synthesis, chromosomal instability, and normal DNA strand break repair. Cancer Res (1989) 0.87
The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int (2000) 0.87
DNA repair characteristics and mutability of the UV-sensitive V79 Chinese hamster cell mutant V-B11 (complementation group 7). Mutagenesis (1991) 0.86
Analysis of repair processes by the determination of the induction of cell killing and mutations in two repair-deficient Chinese hamster ovary cell lines. Mutat Res (1986) 0.86
Stress response induced by DNA damage leads to specific, delayed and untargeted mutations. Mol Gen Genet (1992) 0.85
NCCN: Palliative care. Cancer Control (2001) 0.85
The phospholipase activity of Staphylococcus hyicus lipase strongly depends on a single Ser to Val mutation. Chem Phys Lipids (1998) 0.84
Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer. Urology (1998) 0.84
Study on the variation in X-ray sensitivity of human diploid skin fibroblasts. Normal radiosensitivity of cells derived from patients with Huntington's disease. Mutat Res (1982) 0.84
Melanin content of cultured human melanocytes and UV-induced cytotoxicity. J Photochem Photobiol B (2001) 0.83
Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest (2000) 0.83
Influence of DNA excision repair on UV-induced mutation spectra in Chinese hamster cells. Prog Clin Biol Res (1990) 0.83
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.83
The effect of calf serum on the toxicity of 8-azaguanine. Mutat Res (1975) 0.81
Immortalization of Syrian hamster embryo cells is in itself a multistep event. Cancer Res (1991) 0.81
Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume. Urology (1995) 0.81
Coexpression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in Wilms' tumor. J Pediatr Surg (2000) 0.81
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2001) 0.80
Transformation of C3H10T1/2 cells by N-ethyl-N-nitrosourea occurs as a single, low frequency, mutation-like event. Carcinogenesis (1986) 0.80
Genetic analysis of the susceptibility of mouse cytomegalovirus to acyclovir. J Virol (1985) 0.80
The Chinese hamster V79 cell mutant V-H4 is phenotypically like Fanconi anemia cells. Somat Cell Mol Genet (1990) 0.80
A possible factor in genetic instability of cancer cells: stress-induced secreted proteins lead to decrease in replication fidelity. Carcinogenesis (1992) 0.80
Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology (1993) 0.80
A re-appraisal of the BHK 21 clone-13 cell transformation system with respect to the assay conditions and the mutational origin of the transformed phenotype. Carcinogenesis (1984) 0.80
Oxygen consumption and body fat content of young lean and obese (OB/OB) mice. Proc Soc Exp Biol Med (1978) 0.79